Unibest
← Back to patent-cliff list

Muvalaplin

Tier C — Watch / trade

Muvalaplin

Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：Lp(a)

Indications (approved)：Atherosclerosis, 脂类代谢紊乱, Renal impairment

Regional status

US
Phase III
2025-09-02
EU
Phase III
2025-09-02
China
Phase III
2025-09-02
Japan
Phase III
2025-09-02

Synthetic routes & intermediates3 routes

Originator routes × 2Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield /
(I)1116928-1-a—(II)1116928-1-a90719-32-7(III)1116928-1-a—(IV)1116928-1-a823-78-9(V)1116928-1-a—(VI)1116928-1-a—(VII)1116928-1-a—(VIII)1116928-1-a—(IX)1116928-1-a50978-45-5(X)1116928-1-a,(X)1116928-1-b—(XI)1116928-1-a5470-11-1(XII)1116928-1-a—(XIII)1116928-1-a,(XIII)1116928-1-b—API · Muvalaplin
CodeCAS No.Intermediate
(I)1116928-1-a-(3R)-1-[(1,1-Dimethylethoxy)carbonyl]-3-pyrrolidineacetic acid
(II)1116928-1-a90719-32-7(S)-4-Phenylmethyl-2-oxazolidinone
(III)1116928-1-a-(3R)-3-[2-Oxo-2-[(4S)-2-oxo-4-(phenylmethyl)-3-oxazolidinyl]ethyl]-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester
(IV)1116928-1-a823-78-91-Bromo-3-(bromomethyl)benzene
(V)1116928-1-a-(3R)-3-[(1S)-1-[(3-Bromophenyl)methyl]-2-oxo-2-[(4S)-2-oxo-4-(phenylmethyl)-3-oxazolidinyl]ethyl]-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester
(VI)1116928-1-a-(2S)-3-(3-Bromophenyl)-2-[(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]propanoic acid
(VII)1116928-1-a-Ammonium (2S)-3-(3-bromophenyl)-2-[(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]propanoate
(VIII)1116928-1-a-(alphaS,3R)-alpha-[(3-Bromophenyl)methyl]-1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidineacetic acid 1,1-dimethylethyl ester
(IX)1116928-1-a50978-45-51,1,3-Trioxo-1,2-benzothiazole-2-carbaldehyde
(X)1116928-1-a,(X)1116928-1-b-(alphaS,3R)-1-[(1,1-Dimethylethoxy)carbonyl]-alpha-[(3-formylphenyl)methyl]-3-pyrrolidineacetic acid 1,1-dimethylethyl ester
(XI)1116928-1-a5470-11-1AvailableAmino alcohol hydrochloride
(XII)1116928-1-a-(alphaS,3R)-1-[(1,1-Dimethylethoxy)carbonyl]-alpha-[[3-[(E)-(hydroxyimino)methyl]phenyl]methyl]-3-pyrrolidineacetic acid 1,1-dimethylethyl ester
(XIII)1116928-1-a,(XIII)1116928-1-b-1,1-Dimethylethyl (alphaS,3R)-alpha-[[3-(aminomethyl)phenyl]methyl]-1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidineacetate
OriginatorRoute 2Steps 3 · Total yield /
(X)1116928-1-a,(X)1116928-1-b—(XIII)1116928-1-a,(XIII)1116928-1-b—(XIV)1116928-1-b—(XV)1116928-1-b—API · Muvalaplin
CodeCAS No.Intermediate
(X)1116928-1-a,(X)1116928-1-b-(alphaS,3R)-1-[(1,1-Dimethylethoxy)carbonyl]-alpha-[(3-formylphenyl)methyl]-3-pyrrolidineacetic acid 1,1-dimethylethyl ester
(XIII)1116928-1-a,(XIII)1116928-1-b-1,1-Dimethylethyl (alphaS,3R)-alpha-[[3-(aminomethyl)phenyl]methyl]-1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidineacetate
(XIV)1116928-1-b-Di-tert-butyl (3R,3'R)-3,3'-(azanediylbis[methylene-3,1-phenylene[(2S)-3-tert-butoxy-3-oxopropane-1,2-diyl]])di(pyrrolidine-1-carboxylate)
(XV)1116928-1-b-tert-Butyl (3R)-3-[(2S)-3-[3-[[bis[[3-[(2S)-3-[(2-methylpropan-2-yl)oxy]-2-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenyl]methyl]amino]methyl]phenyl]-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]pyrrolidine-1-carboxylate
OptimisedRoute 3Steps 2 · Total yield /
(I)1116928-2-a—(II)1116928-2-a—(III)1116928-2-a—API · Muvalaplin
CodeCAS No.Intermediate
(I)1116928-2-a-(alphaS,3R)-1-[(1,1-Dimethylethoxy)carbonyl]-alpha-[(3-formylphenyl)methyl]-3-pyrrolidineacetic acid 1,1-dimethylethyl ester
(II)1116928-2-a-tert-Butyl (3R)-3-[(2S)-3-[3-[[bis[[3-[(2S)-3-[(2-methylpropan-2-yl)oxy]-2-[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]-3-oxopropyl]phenyl]methyl]amino]methyl]phenyl]-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]pyrrolidine-1-carboxylate
(III)1116928-2-a-(2S,2'S,2''S)-3,3',3''-((Nitrilotris(methylene))tris(benzene-3,1-diyl))tris(2-((R)-pyrrolidin-3-yl)propanoic acid)

Frequently asked questions

What are the approved indications of Muvalaplin?

Approved indications include: Atherosclerosis, 脂类代谢紊乱, Renal impairment.

When does the Muvalaplin patent expire?

No public expiry year is available for Muvalaplin yet; this page updates once verified.

How many synthesis routes are recorded for Muvalaplin?

3 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Muvalaplin intermediates?

1 intermediate CAS of Muvalaplin are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Muvalaplin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-30